PRINCETON, N.J. and BENGALURU, India, July 11, 2024 (GLOBE NEWSWIRE) -- Indegene
today announced a strategic collaboration with Microsoft to empower global life
sciences companies to scale up the adoption of purpose-built, enterprise-grade
Generative AI (GenAI) services, thereby driving faster innovation at scale.
Indegene and Microsoft have committed to developing resources in highly
specialized and skilled medical and technology tools to co-innovate generative
AI services and workflows across commercial, medical, regulatory, and clinical
functions.
"GenAI presents a once-in-a-decade opportunity for life sciences companies to
modernize business processes and reimagine the effectiveness and efficiency of
their operations throughout the value chain. Using GenAI, we're closely working
with many of our clients to solve specific business problems, with nearly 50
real-world use cases already in an advanced pilot stage," said Tarun Mathur,
CTO, Indegene. "As we double down on efforts to strengthen our innovation
prowess, we will keep exploring opportunities for greater collaboration with key
technology providers. We remain focused on helping our clients harness the
potential of GenAI with targeted solutions to address some of their most
pressing operational challenges and make their business future-ready."
Alok Lall, Chief Operating Officer, Microsoft India?& South Asia, said,
"Generative AI is profoundly shaping every industry, including life sciences, by
offering unprecedented avenues for healthcare technology advancements. According
to a Microsoft-commissioned study conducted by IDC(i), a staggering 79% of
healthcare organizations have now embraced AI. This demonstrates that the
tangible business value of this transformation is indisputable. By seamlessly
integrating Indegene's domain knowledge with Microsoft Azure OpenAI Service and
Microsoft Copilot, we stand at the forefront of advancing generative AI within
the life sciences sector. This collaborative effort empowers life sciences
companies to fully harness AI's capabilities, fostering innovation and
scalability within the industry."
Some of the key use cases the strategic collaboration focuses on in the first
phase, include:
* Content Super App: Using Azure OpenAI Service, the modular content value
chain simplifies content creation and tagging for life sciences companies.
This integrated approach offers a holistic view of the content value chain,
enabling greater velocity, personalized content, and adoption of new
conversation form factors. It also streamlines creative and video
transformation while effectively engaging healthcare professionals (HCPs),
patients and payers
* Future-ready medical content value chain: Generative AI capabilities are
revolutionizing the medical content value chain. From sourcing content from
relevant literature articles to authoring core documents such as Clinical
Study Reports (CSRs) and Protocols, Indegene's solutions accelerate
authoring processes and help ensure compliance across clinical and
regulatory domains
* Data Management and Analytics for Clinical Trials: Using Microsoft Fabric,
Indegene's solutions enhance the process of data ingestion and refinement,
facilitate effortless reporting, and guarantee governance. This leads to
proficient analytics, adherence to compliance, and nimbleness in business
operations. It revolutionizes the way sales users work and provides a
competitive advantage in the marketplace
Indegene counts 20 of the world's top 20 biopharma companies among its clients.
The company brings a practitioner's perspective to enable organizations to
become AI-powered companies. With patients and their health outcomes being the
key, Indegene powers clients' ambition with a practitioner's expertise in
leveraging GenAI, at scale. "With a focus on the right use cases, a responsible
and compliant approach to scaling up, and shared learnings, we put generative AI
to work for our clients," added Tarun.
To develop a future-ready workforce, Indegene has also instituted the 'GenAI @
Work' initiative, where all its 5,000+ employees will be trained on various
facets of GenAI to enhance automation and productivity, allowing its employees
to focus on higher-value tasks. As part of this initiative, Indegene has
deployed Microsoft Copilot in several of its core business processes and has
already started seeing significant productivity improvements.
About Indegene
Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences
commercialization company. It helps biopharmaceutical, emerging biotech,
and medical device companies develop products, get them to the market, and grow
their impact through the life cycle in a more effective, efficient, and modern
way. Indegene brings together healthcare domain expertise, fit-for-purpose
technology, and an agile operating model to provide a diverse range of
solutions. These aim to deliver, amongst other outcomes, a personalized,
scalable, and omnichannel experience for patients and physicians. It's what
drives Indegene's team and their purpose to enable healthcare organizations to
be future-ready. To learn more, please visit www.indegene.com
(http://www.indegene.com/)
For media inquiries, please contact:
Indegene | Yadunandan K V | yadunandan.kv@indegene.com
(https://www.globenewswire.com/Tracker?data=VnPVEGyymnVTv70yJ-
RKLpKknSGYXv1K5rTLlQrn2Wx5loxGXfvYMQ99JLho-
fQxPSZS5q17q2lbIObVxmd43I9P0PxdqW1h4oVT4Ra1HsYKjxoTFLahttHTtkozG1sn)
(___________________________________)
(i) The Business Opportunity of AI | Microsoft AI
(https://info.microsoft.com/ww-landing-idc-delivering-real-business-value-from-
ai.html) - IDC InfoBrief, sponsored by Microsoft, The Business Opportunity of
AI: How Leading Organizations Around the World Are Using AI to Drive Impact
Across Every Industry, IDC #US51364223, Nov. 2023.
Â